Skip to main content
SpringerLink
Log in

Hoe belangrijk is de contra-indicatie diabetes bij bètablokkers?

  • Chapter
De meest gestelde vragen over: Diabetes mellitus

Part of the book series: De meest gestelde vragen over: diabetes mellitus ((MGV))

  • 835 Accesses

Abstract

Deze vraag kan men beter omdraaien. Een betere vraagstelling zou zijn: Hoe belangrijk zijn ß-blokkers bij diabetes?

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 24.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Referenties

  1. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. J Am Med Assoc 1979; 241: 2035–38.

    Article  CAS  Google Scholar 

  2. Fuller JH. Mortality trends and causes of death in diabetic patients. Diabet Metab 1993; 19: 96–99.

    CAS  Google Scholar 

  3. Koistinen MJ. Prevalence of asymptomatic myocardial ischemia in diabetic subjects. Br Med J 1990; 301: 92–95.

    Article  CAS  Google Scholar 

  4. Malmberg K, Herlitz J, Hjalmarson A, Ryden L. Effects of metroprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies. Eur HeartJ 1989; 10: 423–28.

    CAS  Google Scholar 

  5. Kendall MJ, Lynch KP, Hjalmarson A, Kjekhus J. B-blockers and sudden death. Ann Intern Med 1995; 123: 358–67.

    Article  PubMed  CAS  Google Scholar 

  6. Dornhorst A, Powell SH, Pensky J. Aggravation by propanolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion. Lancet 1985; 1: 123–26.

    Article  PubMed  CAS  Google Scholar 

  7. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin dependent diabetes mellitus and hypertension. A randomised controlled trial. Ann Intern Med 1997; 126: 955–59.

    Article  PubMed  CAS  Google Scholar 

  8. Cooper-Dehoff RM, Pacanowski MA, Pepine CJ. Cardiovascur therapies and associated glucose homeostasis: implications across the dysglycemia continuum. JACC 2009; 53: suppl S28-S34.

    Article  PubMed  CAS  Google Scholar 

  9. Singh P, Aronow WS, Mellana WM, Gutwein AH. Prevalence of appropriate management of diabetes mellitus in an academic general medicine clinic. Am J Ther 2009; feb 28 [Epub ahead of print]

    Google Scholar 

  10. The task force for the management of arterial hypertension of the European society of hypertension (ESH) and the European society of cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. Eur HeatJ 2007; 28: 1462–536.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Atrium Medisch Centrum Parkstad, Heerlen en Universiteit Maastricht en M.B. Graal, Ryad, Saudi Arabia

    dr. L. H. B. Baur (cardioloog)

Authors
  1. dr. L. H. B. Baur
    View author publications

    You can also search for this author in PubMed Google Scholar

Copyright information

© 2010 Bohn Stafleu van Loghum

About this chapter

Cite this chapter

Baur, L.H.B. (2010). Hoe belangrijk is de contra-indicatie diabetes bij bètablokkers?. In: De meest gestelde vragen over: Diabetes mellitus. De meest gestelde vragen over: diabetes mellitus. Bohn Stafleu van Loghum, Houten. https://doi.org/10.1007/978-90-313-7342-0_13

Download citation

  • DOI: https://doi.org/10.1007/978-90-313-7342-0_13

  • Publisher Name: Bohn Stafleu van Loghum, Houten

  • Print ISBN: 978-90-313-7341-3

  • Online ISBN: 978-90-313-7342-0

  • eBook Packages: Dutch language eBook collection

Publish with us

Policies and ethics

Search

Navigation